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Background: Metastases to the breast from extramammary malignancies are very rare, and ruling out the
diagnosis of primary breast tumor is important in order to decide on clinical management and predict prognosis.
Case presentation: Clinical examination revealed in a 49-year-old hairdresser a 3-cm hard lump adherent to
the underlying layers in the right breast. Trucut biopsy was performed. Histology showed a solid proliferation of
medium-sized neoplastic polygonal cells. Immunohistochemical analysis showed tumor cells diffusely positive for
cytokeratin 8/18 and calretinin and focally positive for cytokeratin 5/6 and Wilms’ tumor 1, e-cadherin, and human
bone marrow endothelial-1. Estrogen receptors and progesterone receptors were negative. The final diagnosis was
metastatic epithelioid malignant pleural mesothelioma.
Conclusions: Immunohistochemistry is an important tool for a conclusive diagnosis of malignant pleural
mesothelioma. Owing to the degree of histological and immunohistochemical overlap, a high level of clinical
suspicion is essential in order to avoid unnecessary mutilating surgery.
Keywords: Malignant pleural mesothelioma, Breast metastasis, Breast cancerBackground
Breast cancer is the most common malignancy in women,
whereas metastases to the breast from extramammary
malignancies are very rare, accounting for only 0.43% of
all malignant breast tumors [1]. The most common pri-
mary tumors metastasizing to the breast are melanoma
(29.8%), lung carcinoma (16.4%), gynecological carcinoma
(12.7%), intestinal carcinoma (9.9%), leukemia and lym-
phoma (8.4%), rhabdomyosarcoma (7.3%), and renal cell
carcinoma (1.5%) [1]. The time interval between diagnosis
of primary cancer and the appearance of breast metastases
ranges from 1 to 5 years [2]. Differential diagnosis be-
tween primary breast tumor and metastases to the breast
from extramammary malignancies is important in order
to decide on clinical management and predict expected
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article, unless otherwise stated.Malignant pleural mesothelioma (MPM) is a rare and
aggressive tumor with a median survival of 4 to 12
months, officially recognized as an occupational disease
and a signal disease for asbestos exposure [3]. More than
80% of patients with MPM are men [4]. Because the
clinical manifestations of MPM are usually nonspecific,
diagnosis is often delayed, commonly for as much as 6
months [5]. Pemetrexed- and cisplatin-based chemother-
apy is the reference treatment [6].
We report an unusual case of a woman presenting
with a breast mass in which trucut biopsy under
ultrasound guidance enabled assessment of metastatic
MPM.Case presentation
A 49-year-old hairdresser was referred to our Breast
Unit for suspected right breast cancer. A family history
of breast cancer in a first-degree relative was reported.
The patient had no symptoms, such as fever, nightBioMed Central. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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vealed a 3-cm hard lump adherent to the underlying
layers in the right breast and extending into the axillary
tail. Breast sonography showed a solid polylobated mass
(3 × 2.5 cm) with heterogeneous echogenicity and no
acoustic shadowing behind the tumor. Mammograms
were difficult to interpret due to high breast density.
Trucut biopsy was performed.
Histology showed a solid proliferation of medium-sized
neoplastic polygonal cells bearing large round vesicular
nuclei with central nucleoli and moderate amounts of
pale, pinkish cytoplasm. There was little intervening fibril-
lary stroma and no breast parenchyma (Figure 1). Immu-
nohistochemical analysis showed tumor cells diffusely
positive for cytokeratin (CK) 8/18 and calretinin and
focally positive for CK 5/6 and Wilms’ tumor 1 (WT1),
e-cadherin, and human bone marrow endothelial- 1
(HBME-1) (Figure 2). Estrogen receptors (ER), proges-
terone receptors (PgR), epidermal growth factor re-
ceptor 2 (c-erbB 2), anti-human epithelial antigen
(Ber-EP4), thrombomodulin, and carcinoembryonic anti-
gen (CEA) were negative. Proliferation index using Ki-67
was 60%. The final diagnosis was metastatic epithelioid
MPM. Upon further questioning, the patient reported a
history of daily professional use of asbestos-containing
handheld hair dryers.
In order to confirm the diagnosis and assess thoracic ex-
tension, computed tomography (CT) of the chest was per-
formed revealing a parenchymatous neoformation (6 cm)
in the right parietal pleura and a lump near the right axilla
(3 cm) (Figure 3).
The patient refused conventional cancer treatment
preferring alternative therapies. After 9 months, she is
still alive.Figure 1 Hematoxylin and eosin stain (H&E; 96 × 96 dpi).
Infiltrative growth of neoplastic polygonal cells bearing hyperchromatic
and pleomorphic nuclei with large eosinophilic nucleolus and a small
amount of pale, pinkish cytoplasm.Conclusions
Only five cases of metastatic MPM presenting with a
breast mass as the initial sign of the disease are reported
in the literature, two of them affecting male patients.
Ribeiro-Silva et al. and Vergier et al. described the clini-
copathological features of extramammarian malignancies
metastasizing to the breast. In both studies, the primary
sites of the malignancies included one case of mesothe-
lioma, but breast lesion was not the initial sign [7,8].
Sneige et al. reviewed 64 fine-needle aspirates (FNA)
performed on the male breast from 1985 to 1992. One
case of metastatic MPM was found [9]. Sheen-Chen et al.
reported a case of a 51-year-old woman with a large
pleural mesothelioma and an irregular left breast le-
sion (4 × 3.5 cm), which proved to be a metastatic
deposit. Further immunohistochemical study was per-
formed, and the tumor cells were positive for low and
high molecular weight cytokeratin and thrombomodu-
lin and focally positive for CEA [10]. More recently,
Aujayeb et al. presented a case of a 60-year-old male
patient with a right breast mass (13 cm) found to be
a metastatic MPM. Immunohistochemistry showed a
strong positive expression of calretinin, epithelial mem-
brane antigen, WT1, pan-cytokeratin, thrombomodulin,
anti-D240 antibody (D2-40), e-cadherin, and CK 5, 6,
and 7 [11].
Breast metastasis was the first manifestation of MPM
in our patient. The histopathological appearance of MPM
varies and may therefore be a diagnostic challenge, par-
ticularly in the presence of a biopsy specimen of an unre-
lated site. The 2004 World Health Organization (WHO)
classification includes three histological subtypes: epithe-
lioid, sarcomatoid, and biphasic mesothelioma. Rare vari-
ants are desmoplastic type, undifferentiated type, and
deciduoid type. The entirely solid microscopic architec-
ture of the present lesion and the absence of mammary
parenchyma in the biopsy specimen raised suspicion of
primary non-breast malignancy and prompted further in-
vestigation, which led to the correct diagnosis.
Immunohistochemistry is an important tool for a con-
clusive diagnosis of MPM. The main positive MPM
markers include calretinin, WT1, CK 5/6, and HBME-1,
whereas gross cystic disease fluid protein 15 (GCDFP-15)
and mammaglobin are used to confirm breast cancer,
although these markers may be only focally positive
depending on the antibody clone used as well as the
hormone receptor status of the tumor [12].
As reported in Case presentation section the tumor
cells were diffusely positive for calretinin and CK 8/18
and focally positive for CK 5/6, WT1, e-cadherin, and
HBME-1.
Calretinin shows strong nuclear and/or cytoplasmic
positivity in mesothelial cells and is expressed in epithe-
lioid MPM, but not in the sarcomatoid variant of MPM.
Figure 2 Immunohistochemical stainings (96 × 96 dpi). (a) For calretinin, (b) for cytokeratin 8, (c) for cytokeratin 5/6, and (d) for HBME-1
(avidin-streptavidin-peroxidase-DAB).
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[13] as it is expressed in approximately 15% of breast
primary tumors, particularly high-grade, ER-negative,
and basal-like carcinoma. Consequently, calretinin ex-
pression alone could not rule out breast carcinoma in
this case.
CK 8/18 is a low molecular weight cytokeratin found
in simple epithelium and secretory epithelium. CK 8/18
is markedly upregulated in epithelioid MPM, whereas
only ductal in situ carcinoma is diffusely positive for this
luminal cell marker [14]. Accordingly, the positive result
obtained in the present case was useful for ruling out
high-grade invasive breast carcinoma.
CK5/6 is a basal cell marker, which is expressed in
only 10 to 15% of breast tumors, predominantly in
basal-like carcinoma, metaplastic carcinoma, and ade-
noid cystic carcinoma. In contrast, 75 to 100% of MPMs
are CK 5/6-positive [15].
Approximately 75 to 80% of breast tumors are posi-
tive for ER and/or PR, but MPMs are not. However,
this percentage is reduced to only 2% in breast cancer
nuclear grade 3. The present lesion was negative for
ER and PgR [16].
Approximately 15% of breast primary cancers of the
papillary mucinous subtype are positive for WT1, an
independent marker for mesothelioma [17]. However,
the present case did not show papillary mucinousdifferentiation, and WT1 positivity was therefore consist-
ent with a serosal membrane origin of this malignancy.
E-cadherin is normally expressed in the cell membrane
of breast ductal cancer cells but not in mesothelial cells.
Nevertheless, the present tumor presented focal positive
immunostaining, like the case reported by Aujayeb et al.
[11], thereby hampering its specificity for ruling out MPM.
HBME-1 normally reacts with an antigen present in
the membrane of benign and malignant mesothelial
cells, and it was focally expressed in our case. How-
ever, sensitivity of HBME-1 is high while specificity
is low in mesothelial differentiation, as this marker
stains various types of adenocarcinoma. HBME-1 is
also nonreactive with sarcomatous mesothelioma and
with the sarcomatous components of the biphasic
variants [18].
Ber-EP4, thrombomodulin, and CEA were negative in
this case. Ber-EP4 and CEA are expected to be negative
in MPM, but the negativity for thrombomodulin was
surprising, considering that the reported sensitivity and
specificity of thrombomodulin in epithelioid mesotheli-
oma range from 61% to over 80% [19].
According to the limited data reported in the litera-
ture, mesothelioma is immunonegative for both mam-
maglobin and GCDFP-15. Confirmation of breast origin
may therefore be obtained using immunostaining with
mammaglobin, GCDFP-15, and androgen receptor in
Figure 3 CT of the chest (96 × 96 dpi). Sagittal reformatted CT image demonstrates the presence of a parenchymatous neoformation (6 cm) in
the right parietal pleura (white arrow) and of another mass in the right axillary extension (3 cm) (black arrow).
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category of breast carcinoma [20].
In conclusion, as symptomatic metastases of MPM are
unusual and metastases to the breast are very rare, clin-
ical and histological misdiagnosis is possible. Owing to
the degree of histological and immunohistochemical
overlap, a high level of clinical suspicion is essential in
order to avoid unnecessary mutilating surgery. A large
panel of immunoreactions is necessary to establish a cor-
rect diagnosis. We found that CK 8/18, CK 5/6, and
WT1 formed a useful panel in this respect, particularly if
associated with negative results for ER and PR.
Despite the metastatic disease and the refusal of treat-
ment, this patient is still alive after 9 months, possibly
due to the favorable epithelioid histology of the tumor,which is associated with the longest survival (a median
overall survival of 16 months).
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